 | | Vol. 13.02 – 21 January, 2022 |
| |
|
|
| Scientists evaluated growth differentiation factor-15 (GDF15) function using in vivo preclinical prostate cancer (PCa)-bone metastasis mouse models and an in vitro bone cell coculture system and suggested that PCa-secreted GDF15 promoted bone metastases and induced bone microarchitectural alterations.
[Bone Research] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that EZH2 inhibitors could block the transactivation activity of EZH2 and inhibit the growth of CRPC cells, which revealed a previously unappreciated mechanism of action of EZH2 inhibitors and provided a mechanistic basis for potential combination cancer therapies.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers explored the prognostic potential and the functional role of microRNAs in localized prostate cancer and their relation to nodal metastasis.
[Oncogene] |
|
|
|
| Combination therapy with the transforming growth factor-β receptor I kinase inhibitor SD-208 and a toll-like receptor-7/8 agonist resiquimod was examined along with serum-derived exosomes as versatile carriers and may serve as a promising strategy to treat melanoma and prostate cancer.
[Acta Biomaterialia] |
|
|
|
| As cholesterol is a key substrate for de novo steroidogenesis in prostate cells, scientists hypothesized that castrate-resistant/advanced prostate cancer cell growth was influenced by the availability of extracellular, low-density lipoprotein (LDL)-derived, cholesterol coupled to intracellular cholesteryl ester homeostasis.
[Cancer & Metabolism] |
|
|
|
| Using human cell lines that represent androgen-independent or -sensitive prostate cancer, the authors showed that mitochondrial Rho GTPase 2 (MIRO2) depletion impaired cell growth, colony formation, and tumor growth in mice.
[Molecular Cancer Research] |
|
|
|
| Investigators assessed the stage-specific expression of zinc transporters (ZNTs) belonging to the ZNT (SLC30A) and Zrt- and Irt-like protein (SLC39A) solute-carrier family in the prostate tissues of different genetically engineered mouse models of prostate cancer, their age-matched wild-type controls, and 104 prostate core biopsies from human patients with different pathological lesions.
[Molecular Carcinogenesis] |
|
|
|
| Abiraterone, an inhibitor of the steroidogenic enzyme CYP17A1, has been demonstrated to reduce adrenal androgen synthesis and prolong CRPC patient survival. To study mechanisms of resistance to castration and abiraterone, researchers created coculture models using human prostate and adrenal tumors.
[Prostate] |
|
|
|
| Scientists studied the effect of co-treatment of caffeic acid phenethyl ester (CAPE) and gamma radiation on androgen-independent DU145 and PC3 cells. The combination treatment sensitized prostate cancer cells to radiation in a dose-dependent manner. The radiosensitizing effect of CAPE was observed in both cell lines.
[Environmental Toxicology] |
|
|
|
|
| The authors summarize the data on the discovery, modeling, molecular taxonomy, lineage plasticity and therapeutic targeting of ETS family members in prostate cancer.
[Cancer Letters] |
|
|
|
| Investigators present completed and ongoing research projects regarding prostate cancer immunotherapy. Ipilimumab and olaparib were proved to prolong overall survival significantly against placebo, but a lot of research is going on to identify which patients and at what stage of disease will benefit the most.
[Expert Opinion On Biological Therapy] |
|
|
|
|
| Profound Medical Corp. announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial, a prospective, multi-center randomized controlled trial of 201 patients aimed at comparing the safety and efficacy of the TULSA procedure with radical prostatectomy in men with prostate cancer.
[Profound Medical Corp. (GlobeNewswire, Inc.)] |
|
|
|
|
|
|
|
| | Henry M. Jackson Foundation for the Advancement of Military Medicine – Bethesda, Maryland, United States |
|
|
|
| | University of Maryland, Baltimore – Baltimore, Maryland, United States |
|
|
|
| | Wayne State University School of Medicine – Detroit, Michigan, United States |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
